All In Biotech

Drug Trial Radar · NCT07879170

A Single and Multiple Ascending Dose Study of EPX-100 in Healthy Adult Participants

A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study to Assess the Safety and Pharmacokinetics of Ascending Single and Multiple Doses of EPX-100 in Healthy Adult Participants

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

88

Planned (sponsor's estimate)

Start

Aug 5, 2026

Primary completion

Dec 30, 2026

Study completion Dec 30, 2026

Sponsor

Lead sponsor
EpygenixIndustry
Sponsor type
Industry
Collaborators
Harmony Biosciences Management, Inc.
First posted
Oct 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A study to evaluate the safety and tolerability of single and multiple ascending doses of EPX-100 in healthy adult participants.

Conditions

  • Healthy Participants

Interventions

  • EPX-100Drug

    Oral solution

  • EPX-100-Matching PlaceboDrug

    Oral Solution

  • MoxifloxacinDrug

    Over-encapsulated tablet

  • Moxifloxacin-Matching PlaceboDrug

    Capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment Emergent Adverse Events (TEAEs) in Part 1 SADTime frame: Part 1 SAD: up to Day 18
  2. Number of Participants with TEAEs in Part 2 MADTime frame: Part 2 MAD: up to Day 31

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion

    Tempe, Arizona · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.